Intracavitary therapies for mesothelioma

Current Treatment Options in Oncology

Volumn 2, Issue 5, 2001, Pages 385-394

  Verschraegen, Claire F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Irinotecan; Main Side Effect; Malignant Pleural Mesothelioma; Peritoneal Carcinomatosis; Suramin

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; MITOXANTRONE;

ADJUVANT CHEMOTHERAPY; ADOPTIVE IMMUNOTHERAPY; EPIDEMIOLOGY; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; MESOTHELIOMA; PERITONEUM TUMOR; PLEURA TUMOR; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; EPIDEMIOLOGIC METHODS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS, INTRAPERITONEAL; MESOTHELIOMA; MITOXANTRONE; PERITONEAL NEOPLASMS; PLEURAL NEOPLASMS; TREATMENT OUTCOME;

EID: 0035496510     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-001-0043-3     Document Type: Article

References (50)

1. Antman KH. Current Concepts: Malignant mesothelioma. N Engl J Med 1980, 303:200–202. DOI: 10.1056/NEJM198007243030407
2. Rusch VW: A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer 1996, 14:1–12. DOI: 10.1016/0169-5002(95)00508-0
3. Gross-Goupil M, Ruffie P: Malignant pleural mesothelioma. Bull Cancer 1999, 3 (suppl):43–54. Key information for the clinician.
4. Alberts DS, Liu PY, Hannigan EV, et al.: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996, 335:1950–1955. DOI: 10.1056/NEJM199612263352603
5. Panteix G, Guillaumont M, Cherpin L, et al.: Study of the pharmacokinetics of mitomycin C in humans during intraperitoneal chemohyperthermia with special mention of the concentration in local tissues. Oncology 1993, 50:366–370. DOI: 10.1159/000227211
6. Markman M. Intraperitoneal therapy of ovarian cancer. Semin Oncol 1998, 25:356–60.
7. Merrin C. Treatment of advanced bladder cancer with cis-diamminedichloroplatinum (II NSC 119875): a pilot study. J Urol 1978, 119:493–495.
8. Mune T, Yasuda K, Ishii M, Matsunaga T, Miura K. Tetany due to hypomagnesemia induced by cisplatin and doxorubicin treatment for synovial sarcoma. [review]. Intern Med 1993, 32:434–437.
9. Thompson SW, Davis LE, Kornfeld M, et al.: Cisplatin neuropathy: clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 1984, 54:1269–1275. DOI: 10.1002/1097-0142(19841001)54:7<1269::AID-CNCR2820540707>3.0.CO;2-9
10. Verschraegen C, Conrad CA, Hong WK. Subacute encephalopathic toxicity of cisplatin. Lung Cancer 1995,13:305–309. DOI: 10.1016/0169-5002(95)00503-X
11. Rusch VW, Niedzwiecki D, Tao Y, et al.: Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies. J Clin Oncol 1992,10:1001–1006.
12. Markman M, Cleary S, Pfeifle C, Howell SB: Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma. Cancer 1986, 58:18–21. DOI: 10.1002/1097-0142(19860701)58:1<18::AID-CNCR2820580105>3.0.CO;2-C
13. Aitini E, Pasquini E, Cavazzini G, et al.: Local treatment of malignant pleural mesothelioma with intracavitary cytosine-arabinoside and cisplatin [letter]. Ann Oncol 1992, 3:771–772.
14. Markman M, Howell SB. Daily intraperitoneal administration of cytarabine in a patient with peritoneal mesothelioma. Cancer Drug Deliv 1985, 2:285–289.
15. Aitini E, Cavazzini G, Pasquini E, et al.: Treatment of primary or metastatic pleural effusion with intracavitary cytosine arabinoside and cisplatin. A phase II study. Acta Oncol 1994, 33:191–194.
16. Markman M, Kelsen D: Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 1992, 118:547–50. DOI: 10.1007/BF01225271
17. Hayashi T, Nasu Y, Aramaki K, et al.: A case of peritoneal malignant mesothelioma with disappearance of ascites result of intraperitoneal instillation of mitomycin C and oral administration of UFT. Gan to Kagaku Ryoho 1989, 16:2449–2452.
18. Langer CJ, Rosenblum N, Hogan M, et al.: Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: favorable outcome with a multimodality approach. Cancer Chemother Pharmacol 1993, 32:204–208. DOI: 10.1007/BF00685836
19. Ito H, Imada T, Kondo J, et al.: A case of malignant peritoneal mesothelioma showed complete remission with chemotherapy. Jpn J Clin Oncol 1998, 28:145–148. DOI: 10.1093/jjco/28.2.145
20. Nakano T, Chahinian AP, Shinjo M, et al.: Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile. Cancer 1999, 85:2375–2384. Provides much-needed documentation. DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2375::AID-CNCR12>3.0.CO;2-E
21. Verschraegen C, Le D, Kudelka A, et al.: Cisplatin and irinotecan for peritoneal mesothelioma. Proc Am Soc Clin Oncol 2001, 20:A2110. Excellent study.
22. Bleiberg H, Cvitkovic E: Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective. [review]. Eur J Cancer 1996, 32A(suppl 3):S18-S23. DOI: 10.1016/0959-8049(96)00293-6
23. Rothenberg ML, Kuhn JG, Burris HA, et al.: Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 1993, 11:2194–2204.
24. de Forni M, Bugat R, Chabot GG, et al.: Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 1994, 54:4347–4354.
25. Abigerges D, Chabot GG, Armand JP, et al.: Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995, 13:210–221.
26. Verschraegen CF, Levy T, Kudelka AP, et al.: Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 1997, 15:625–631.
27. Masuda N, Fukuoka M, Kusunoki Y, et al.: CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992:10:1225–1229.
28. Han I, Ling YH, al-Baker S, et al.: Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells. Cancer Res 1993, 53:4913–4919.
29. Khokhar AR, Wright K, Siddik ZH, Perez-Soler R: Organ distribution and tumor uptake of liposome entrapped cis-bis-neodecanoato trans-R, R-1, 2 diaminocyclohexane platinum (Ii) administered intravenously and into the proper hepatic artery. Cancer Chemother Pharmacol 1988, 22:223–227. DOI: 10.1007/BF00273415
30. Khokhar AR, al-Baker S, Krakoff IH, Perez-Soler R: Toxicity and antitumor activity of cis-bis-carboxylato (trans-R,R-1,2-diaminocyclohexane) platinum(Ii) complexes Entrapped in Liposomes. Cancer Chemother Pharmacol 1989, 23:219–224. DOI: 10.1007/BF00451645
31. Perez-Soler R, Yang LY, Drewinko B, et al.: Increased cytotoxicity and reversal of resistance to cisdiamminedichloro-platinum(Ii) with entrapment of cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (Ii) in multilamellar lipid vesicles. Cancer Res 1988, 48:4509–4512.
32. Perez-Soler R, Shin DM, Siddik ZH, et al.: Phase I clinical and pharmacological study of liposomeentrapped NDDP administered intrapleurally in patients with malignant pleural effusions. Clin Cancer Res 1997, 3:373–379.
33. VerschraegenC, Mansfield P, Feig B, et al.: Phase I study of an intraperitoneal liposomal cisplatin analog (L-NDDP) for treatment of peritoneal carcinomatosis [abstract]. Proc ASCO 1999, 18:1405. Provides key data.
34. Perez-Soler R, Lopez-Berestein G, Lautersztain J, et al.: Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R, R-1,2-diaminocyclohexane platinum(Ii). Cancer Res 1990, 50:4254–4259.
35. Verschraegen C, Mansfield P, Feig B, et al.: Phase I study of an intraperitoneal liposomal cisplatin analog L-NDDP for treatment of peritoneal carcinomatosis [abstract]. Proc ASCO 1999, 18:A1405.
36. Westermann AM, Dubbelman R, Moolenaar WH, et al.: Successful intraperitoneal suramin treatment of peritoneal mesothelioma. Ann of Oncol 1997, 8:801–802. DOI: 10.1023/A:1008231901539
37. WestermannAM, Dubbelman R, Baars JP, et al.: Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy. Cancer Chemother Pharmacol 2000, 46:57–62. Provides much-needed documentation. DOI: 10.1007/s002800000116
38. Vlasveld LT, Taal BG, Kroon BB, et al.: Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone. Cancer Chemother Pharmacol 1992, 29:405–408. DOI: 10.1007/BF00686012
39. Ardizzoni A, Pennucci MC, Castagneto B, et al.: Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesothelioma. Am J Clin Oncol 1994, 17:80–82. DOI: 10.1097/00000421-199402000-00018
40. Boutin C, Nussbaum E, Monnet I, et al.: Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer 1994, 74:2460–2467. DOI: 10.1002/1097-0142(19941101)74:9<2460::AID-CNCR2820740912>3.0.CO;2-N
41. Tani M, Tanimura H, Yamaue H, et al.: Successful immunochemotherapy for patients with malignant mesothelioma: report of two cases. Surg Today 1998, 28:647–651. DOI: 10.1007/s005950050200
42. Cain J, Nori D, Huvos A, Erlandson RA, et al.: The role of radioactive colloids in malignant peritoneal mesotheliomas. Gynecol Oncol 1983, 16:263–274. DOI: 10.1016/0090-8258(83)90101-4
43. Reuter K, Raptopoulos V, Reale F, et al.: Diagnosis of peritoneal mesothelioma: computed tomography, sonography, and fine-needle aspiration biopsy. Am J Roentgenol 1983,140:1189–1194.
44. Muensterer OJ, Averbach AM, Jacquet P, et al.: Malignant peritoneal mesothelioma. Case-report demonstrating pitfalls of diagnostic laparoscopy. Int Surg 1997, 82:240–243.
45. Neuhaus SJ, Texler M, Hewett PJ, Watson DI: Port-site metastases following laparoscopic surgery. Br J Surg 1998, 85:735–7341. DOI: 10.1046/j.1365-2168.1998.00769.x
46. Sebbag G, Yan H, Shmookler BM, et al.: Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg 2000, 87:1587–1593. DOI: 10.1046/j.1365-2168.2000.01571.x
47. Sauter ER, Langer C, Coia LR, et al.: Optimal management of malignant mesothelioma after subtotal pleurectomy: revisiting the role of intrapleural chemotherapy and postoperative radiation. J Surg Oncol 1995, 60:100–105. DOI: 10.1002/jso.2930600207
48. Colleoni M, Sartori F, Calabro F, et al.: Surgery followed by intracavitary plus systemic chemotherapy in malignant pleural mesothelioma. Tumori 1996, 82:53–56.
49. Averbach AM, Sugarbaker PH: Peritoneal mesothelioma: treatment approach based on natural history. Cancer Treat Res 1996, 81:193–211.
50. Vlasveld LT, Gallee MP, Rodenhuis S, Taal BG: Intraperitoneal chemotherapy for malignant peritoneal mesothelioma. Eur J Cancer 1991, 27:732–734. DOI: 10.1016/0277-5379(91)90176-E